Barclays’s PhenomeX Inc. Common Stock CELL Stock Holding History

Barclays’s Portfolio CELL Stock Details CELL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-63,503	Closed	-$63.4K	–	5452
2023 Q3	$63.4K	Buy	63,503 +53,899	+561%	+$41.3K	﹤0.01%	3761
2023 Q2	$4.71K	Sell	9,604 -34,414	-78%	-$28.2K	﹤0.01%	4279
2023 Q1	$51.1K	Buy	44,018 +19,301	+78%	+$35.3K	﹤0.01%	4436
2022 Q4	$66.2K	Buy	24,717 +9,798	+66%	+$25.8K	﹤0.01%	4440
2022 Q3	$42K	Sell	14,919 -59,752	-80%	-$254K	﹤0.01%	3833
2022 Q2	$371K	Buy	74,671 +55,379	+287%	+$290K	﹤0.01%	3063
2022 Q1	$137K	Buy	+19,292	New	+$160K	﹤0.01%	3639

Barclays's CELL Position: Q4 2023 in Review

Barclays sold out of PhenomeX Inc. Common Stock (CELL) in Q4 2023, closing a stake of 63,503 shares — an estimated $63.4K sold.

Barclays first reported a position in CELL in Q1 2022 and held it in 7 quarters. The position peaked at $371K in Q2 2022. 0 funds tracked by Wall St. Rank hold CELL as of Q4 2023.

Barclays reported no remaining PhenomeX Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Barclays sold 63,503 PhenomeX Inc. Common Stock shares in Q4 2023, an estimated $63.4K.
Barclays first reported a position in PhenomeX Inc. Common Stock in Q1 2022 and held it in 7 quarters.
Barclays's PhenomeX Inc. Common Stock position peaked at $371K in Q2 2022.
0 funds tracked by Wall St. Rank held PhenomeX Inc. Common Stock as of Q4 2023.

Based on Barclays's 13F filing for Q4 2023, filed 15 Feb 2024.